Politics and Policy

Healthcare experts detail three policies that MCOs should keep a close eye on.

Managed Healthcare Executive asked experts to identify Trump’s top priorities within the plan, and how those priorities could affect managed care.

Managed Healthcare Executive asked experts to weigh in on Trump’s new blueprint to tackle drug market challenges. Here’s what they said.

Healthcare executives must understand mental health laws so they can do the right thing by their patients-and protect their bottom line.

FDA’s new guidance provides a roadmap for health executives on incorporating EHRs into clinical trials.

The 30-year old regulation is in desperate need of modernization to fall in line with the changing needs of healthcare.

Although Kavanaugh's paper trail on health policy is not vast, it does include some intriguing clues about how he might rule on future cases. Find out more.

A new study reveals what has happened in several areas of healthcare delivery following the ACA Medicaid expansion.

The Trump Administration says AHPs will provide small businesses with more choices, access, and coverage options. Here’s what you need to know.

An RFI presents an important opportunity for the healthcare industry to educate CMS on current experiences and challenges.

State policy variations related to these plans could have significant impacts on the overall insurance market. Here’s what you need to know.

When insurers stopped receiving cost-sharing reduction payments from the government last year, many significantly upped premiums for certain health plans. Here’s more on why they did it, what they did, and six things healthcare executives should know.

Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.

The law opens up new options for terminally ill patients. But how will it impact managed care organizations?

Cambia Health Solutions’ Laurent Rotival, MS, reveals what can happen when Amazon’s principles muscle in on the traditional healthcare model.

From the frontlines of healthcare, Sarah Krevans, MBA, MPH, Sutter Health, offers AHIP attendees her ideas on healthcare transformation, future outlook, and consumer empowerment.

Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.

The goal is to help ensure that prescription drug marketing information for consumers and healthcare providers is truthful and balanced. Here’s what the agency plans to research.

Experts weigh in on a recent lawsuit against PBMs, whether similar lawsuits will crop up, and the likely outcomes.

Here are 10 important issues to consider when handling workplace harassment complaints.

About half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.

Sadly, President Trump has issued an executive order to expand these plans under the guise of consumer choice and lower costs.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.

A Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.

CMS unveiled a voluntary episode bundled payment model, Bundled Payments for Care Improvement Advanced (BPCI Advanced). Here’s six things experts want you to know

How did Trump’s actions in 2017 impact the health insurance marketplace and enrollment numbers? Find out.

Trump’s new proposal would broaden access to association health plans. Here’s six things to know.

Managed Healthcare Executive board members identify top challenges. How does your list compare?

This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.